Cynvenio Biosystems Wins ABBY Award for its LiquidBiopsy Platform

November 5, 2014 – Cynvenio announced that it was awarded a 2014 ABBY Award by the Adaptive Business Leaders Organization (ABL) during its 15th annual Innovations in HealthcareSM Leadership Event, held October 28 in San Francisco. The ABBY award recognizes innovative organizations and individuals who are dramatically reducing the cost of quality healthcare through their medical or information technologies, or innovative approaches to the delivery of healthcare.

Cynvenio Biosystems Named Finalist for Patrick Soon-Shiong Innovation Awards

November 05, 2014 – Cynvenio announced that it has been named a finalist for the Los Angeles Business Journal's 2014 Patrick Soon-Shiong Innovation Awards. The awards program, now in its fifth year, was created to celebrate the region’s most impactful innovators who, alongside Dr. Soon-Shiong, CEO at NantWorks, LLC, play an important role in enhancing the economic competitiveness of the region.

ClearID Breast Cancer Genomic Test is Now Reimbursable Under Most Health Insurance Plans

LOS ANGELES, September 16, 2014 – Cynvenio Biosystems, Inc. announces that it will be accepting payment for its ClearID Breast Cancer test under most health insurance plans including Aetna, UnitedHealth Group, Cigna, Assurant, Blue Cross/Blue Shield, Humana, Kaiser Permanente and various Health Maintenance Organizations (HMO), with the exception of Medicaid.

The ASCO Post: Potential of Liquid Biopsies in Detecting Cancer and Establishing Prognosis

September 15, 2014 - The ASCO Post talked with Dr. ­Cristofanilli, a member of Cynvenio's clinical advisory board, about the accuracy of liquid biopsies in detecting and analyzing cancer, their potential use as a tool for cancer screening in healthy people, and how they can provide accurate prognostic information in patients with recurrent disease.

77WABC Radio's Optimal Wellness Hour Features Interview with Andre' de Fusco

September 14, 2014 - Jennifer Smith of 77WABC Radio's Optimal Wellness hour, hosts the second of two interviews discussing the ClearID test.  In this show focused on Breast Cancer awareness, Jennifer speaks with returning guest, Dr. Joe Bosiljevac, and Cynvenio's CEO, Andre' de Fusco.

GenomeWeb: Cynvenio Looks to Add Cell-free DNA Analysis to Circulating Tumor Cell Platform

Sept. 10, 2014 - In this Clinical Sequencing News article published by GenomeWeb, Paul Dempsey, Ph.D., Cynvenio’s CSO, is interviewed about the company’s research and activities to establish the utility of cell-free DNA relative to, and potentially in combination with CTC analysis.   [Premium Subscriber Content]

Cynvenio Biosystems Launches LiquidBiopsy™ Early Access Program for dynamically sequencing patient tumors from whole blood

LOS ANGELES, September 4, 2014 – Cynvenio Biosystems, Inc. announced the launch of a new commercial program granting early access to its LiquidBiopsy Rare Cell Isolation Platform. The LiquidBiopsy system automates the identification and enrichment of rare tumor cells from standard patient blood draws